• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Dollar sign thermometer
Great expectations

Lukewarm start to year weighs heavily on sector’s performance

Feb. 3, 2020
By Peter Winter
Biotech investors had every reason to feel bullish heading into the new decade. The sector had turned around in 2019 and was riding a wave of a very strong fourth-quarter performance, with the BioWorld Biopharmaceutical Index closing up 14% for the year after being underwater from April through to September. Unfortunately, those great expectations were quickly erased during J.P. Morgan Healthcare conference week (Jan. 10 – Jan. 17), which turned out to be a very low-key affair absent of any blockbuster M&A revelations. As a result, confidence has now given way to concerns about the prospects for biopharmaceutical companies going forward, particularly as unfavorable political rhetoric on drug pricing will certainly be dialed up during this election year.
Read More

Week in review for Jan. 27-31, 2020: Long-term view needed for cost of gene therapies

Feb. 3, 2020
By Peter Winter
A quick look back at top stories.
Read More

Money raised by biopharma: 2020 vs. 2019

Jan. 31, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-30, 2020

Jan. 31, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Wall Street sign

Completed and pending biopharma IPOs in January 2020

Jan. 31, 2020
Completed and pending initial public offerings by biopharma companies, including: Annovis Bio, Black Diamond, I-Mab, Nyrada.
Read More
Hand holding gear, dollar sign

Biopharma money raised by quarter in 2019 (US$M)

Jan. 31, 2020
Biopharma money raised to-date and by quarter in 2019, including public, private and other financings.
Read More

Follow-on offerings of biopharma companies in January 2020

Jan. 31, 2020
Follow-ons completed by biopharma companies, including: Adaptimmune, Albireo, Alector, Apellis, Applied, Aptinyx, Autolus, Biohaven, Blueprint Medicines, Catabasis, Concert, DBV, Denali, Heat Biologics, Hutchison China Meditech, Immunogen, Intelgenx, Intra-Cellular, Matinas, Mirati, Mirum, Nanoviricides, Osmotica, Trillium, Xenon, Zai Lab, Zymeworks.
Read More

Other financings of public biotechnology companies in January 2020

Jan. 31, 2020
Private placements and other private financings of public biopharma companies, including: Advaxis, Algernon, Alimera, Armata, Azurrx, Bergenbio, Biocurepharm Korea, Bonus Biogroup, Cellect, Chemocentryx, Cidara, Clovis, Cocrystal, Edesa, Epizyme, Eyegate, Genprex, Helix, Hemogenyx, Hemostemix, Infinity, Iterum, Kamada, Leap, Lineage Cell, Novus, Noxxon, Promis, Puretech, Saniona, Sellas, Seneca, Spero, Tetra, Tetraphase, Titan, Vaxil, Vitro, Wize.
Read More

Venture capital and other private biopharma financings in January 2020

Jan. 31, 2020
Venture capital and other private financings of private biopharma companies, including: Adagene, Aegle, Agilvax, Airway, Alderaan, Aligos, Arpeggio, Biograil, Biointervene, Bionetix, Calidi, Cerebral, Codagenix, Domain, Empirico, Eqrx, Fusion, Genesen, Heparegenix, Idbydna, Immuneering, Jasper, Kyverna, Lyra, Nference, Northsea, Seekyo, Tarsus, Treadwell, Tscan, Tyra, Urania, Vectivbio.
Read More

Milestone payments from corporate partners in January 2020

Jan. 31, 2020
Triggered milestone payments disclosed by biopharma companies, including: BMS, Evotec, Gilead, Newsoara, Roche, Scholar Rock, Seattle Genetics, Zenith Epigenetics.
Read More
Previous 1 2 … 239 240 241 242 243 244 245 246 247 … 264 265 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • Stock chart, upward arrow

    An early stage 85% remissions rate in AML drives Aptevo’s stock surge

    BioWorld
    An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • 3D illustration of a chain of amino acid or biomolecules called protein

    Alphadesign: AI creating proteins from scratch

    BioWorld Science
    The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe